Lupus nephritis: a modern treatment paradigm
Journal Title: Нирки - Year 2018, Vol 7, Issue 2
Abstract
Lupus nephritis is the most common and life-threatening manifestation of systemic lupus erythematosus (SLE) and continues to cause a high percentage of terminal renal failure. The modern treatment of lupus nephritis, as well as new therapeutic strategies, is described in this review. Diagnosis of kidney damage in SLE (lupus nephritis), according to the recommendations of ACR, is based on the following criteria: clinical and laboratory manifestations in the form of proteinuria > 0.5 g/day (or more than 3 “+” when using test strips) and/or the presence of cellular clusters, including clusters of erythrocytes and cylinders (hemoglobin, granular, tubular or mixed). Additional criteria are the results of histological examination of the kidney biopsy with confirmation of the presence of immune complex kidneys damage characteristic of lupus nephritis. The management of lupus nephritis patients consists of two successive phases: initial (induction) and supporting, when combinations of glucocorticoids and immunosuppressors are used. During the induction phase, intensive treatment with glucocorticoids in combination with other immunosuppressants is carried out to rapidly suppress the immune complex renal inflammation and to stop the development of their damage. The aim of this approach and the main task of induction therapy are the restoration of renal function and induction of remission by monitoring the immunological activity of the process. Supportive therapy is used to fix remission and to prevent exacerbations by using drugs or treatment regimens with less risk of complications. Despite the disappointing results of several recent studies, new methods of treatment aimed at various immunological pathways are being actively studied in lupus nephritis. The most promising direction is therapy aimed at B-cells. Deepening understanding of the pathogenesis of lupus nephritis, developing new treatments and optimizing the design of clinical trials will ensure the successful development and introduction of new drugs for lupus.
Authors and Affiliations
I. Yu. Golovach
Keywords
Related Articles
- EP ID EP280847
- DOI 10.22141/2307-1257.7.2.2018.127399
- Views 93
- Downloads 0
Influence of phytotherapy on metabolic status and urine microbiota in patients with urolithiasis — calcium oxalate nephrolithiasis after shock wave lithotripsy
Background. The study of the problem of urolithiasis in recent years has reached a qualitatively new level in connection with the use of a multidisciplinary approach and the principles of evidence-based medicine. In the...
Hyperuricemia — an independent factor for the progression of chronic kidney disease
Objective of the research — to evaluate the efficacy of combined hypouricemic therapy in patients with hyperuricemia, urate nephropathy on the background of concomitant pathology (type 2 diabetes mellitus, hypertension)...
Effect of Albuminuria on the State of Plasma Hemostasis in Patients with Essential Hypertension
In recent decades, numerous scientific works are devoted to the study of the clinical and prognostic significance of albuminuria, methods of its detection, as well as treatment measures aimed at controlling this patholog...
Main Nutritional Lithogenic Factors in Diets of Polish Patients with Kidney Stones
Background. Nutrition is one of the most important determinants of kidney stone formation. This study was designed to evaluate lithogenic factors in diet of patients with renal calculi. Materials and methods. 40 stone-f...
Cryoglobulin Vasculitis Associated with Hepatitis C (Clinical Case)
.